STEVEN E FERN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
- Where
- SULLIVAN, MO
- NPI
- 1417982760
- Received
- $17,921 in 644 records, 2019 to 2025
- As principal investigator
- $1,245,629 of research payments to others in 358 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 12 | $521 |
| 2024 | General payment | 46 | $1,453 |
| 2023 | General payment | 82 | $1,485 |
| 2022 | General payment | 89 | $1,595 |
| 2021 | General payment | 125 | $2,804 |
| 2020 | General payment | 143 | $7,297 |
| 2019 | General payment | 147 | $2,761 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 636 | $12,833 |
| Honoraria | 2 | $4,040 |
| Travel and Lodging | 3 | $1,014 |
| Gift | 1 | $14 |
| Entertainment | 1 | $11 |
| Education | 1 | $6 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-05-14 | GENZYME CORPORATION | $121 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-03-25 | Exact Sciences Corporation | $14 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-03-24 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-21 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-03-13 | Madrigal Pharmaceuticals | $103 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-03-10 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-01-31 | Otsuka America Pharmaceutical, Inc. | $22 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-01-23 | Madrigal Pharmaceuticals | $21 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-01-16 | Exact Sciences Corporation | $18 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-01-14 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2024-12-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-12-12 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-12-03 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-19 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-10-22 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-10-21 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-09 | Gilead Sciences, Inc. | $118 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-10-04 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-10-01 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-09-26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-09-25 | Janssen Biotech, Inc. | $118 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-09-19 | ABBVIE INC. | $84 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-09-19 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-09-19 | Gilead Sciences, Inc. | $1 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-10 | Celgene Corporation | $19 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-09-05 | ABBVIE INC. | $109 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-08-28 | Phathom Pharmaceuticals, Inc. | $109 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-08-27 | Sumitomo Pharma America, Inc. | $16 | Food and Beverage | In-kind items and services | GEMTESA Drug, UROLOGY | 2024 | |
| 2024-08-16 | Phathom Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-07-29 | Celgene Corporation | $19 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-07-22 | GENZYME CORPORATION | $38 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-07-16 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-07-02 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-07-01 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-06-25 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | FABRAZYME Biological, Genetic Disease | 2024 | |
| 2024-06-18 | Phathom Pharmaceuticals, Inc. | $73 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-06-18 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-11 | Janssen Pharmaceuticals, Inc | $21 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2024 | |
| 2024-06-06 | Sumitomo Pharma America, Inc. | $15 | Food and Beverage | In-kind items and services | GEMTESA Drug, UROLOGY | 2024 | |
| 2024-05-23 | Phathom Pharmaceuticals, Inc. | $125 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-05-23 | Exact Sciences Corporation | $14 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-05-14 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-05-13 | GENZYME CORPORATION | $42 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-05-10 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-04-19 | Phathom Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-04-04 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2024 | |
| 2024-03-22 | ABIOMED | $20 | Food and Beverage | In-kind items and services | Impella Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-03-21 | Gilead Sciences, Inc. | $18 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-20 | Gilead Sciences, Inc. | $1 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-07 | Fresenius Kabi USA, LLC | $14 | Food and Beverage | In-kind items and services | IDACIO Biological, Biosimilars | 2024 | |
| 2024-02-27 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2024 | |
| 2024-02-12 | Mirum Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2024 | |
| 2024-02-02 | GENZYME CORPORATION | $117 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-01-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-01-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2023-12-19 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-12-13 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-12-06 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-11-27 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2023 | |
| 2023-11-23 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-11-20 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-11-17 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-11-14 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-11-03 | GENZYME CORPORATION | $8 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-11-01 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-10-23 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-10-19 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-10-11 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-10-11 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-10-11 | Fresenius Kabi USA, LLC | $15 | Food and Beverage | In-kind items and services | IDACIO Biological, Biosimilars | 2023 | |
| 2023-10-11 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-10-10 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-10-09 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-10-02 | NESTLE HEALTHCARE NUTRITION INC. | $15 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2023 | |
| 2023-09-28 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-09-22 | Mirum Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2023 | |
| 2023-09-15 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-09-13 | QOL Medical, LLC | $5 | Food and Beverage | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2023 | |
| 2023-09-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-08-30 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-08-25 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-08-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-08-21 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-08-05 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-08-02 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-07-31 | NESTLE HEALTHCARE NUTRITION INC. | $15 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2023 | |
| 2023-07-26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-07-24 | Celgene Corporation | $16 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-07-11 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-07-07 | GENZYME CORPORATION | $12 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-06-28 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-06-23 | Celgene Corporation | $19 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-06-21 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-06-21 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-06-14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-06-13 | QOL Medical, LLC | $23 | Food and Beverage | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2023 | |
| 2023-06-06 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-06-05 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-06-03 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VIBERZI Drug, GASTROENTEROLOGY | 2023 | |
| 2023-05-31 | NESTLE HEALTHCARE NUTRITION INC. | $16 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2023 | |
| 2023-05-31 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-05-24 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-05-23 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-05-23 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2023 | |
| 2023-05-15 | Celgene Corporation | $14 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-05-08 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-05-02 | RedHill Biopharma Inc. | $18 | Food and Beverage | Cash or cash equivalent | Movantik Drug, Opioid Antagonist | 2023 | |
| 2023-05-02 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-05-01 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-04-28 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2023-04-27 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-04-27 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-04-26 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2023 | |
| 2023-04-26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $9 | Food and Beverage | In-kind items and services | TRULANCE Drug, Gastroenterology | 2023 | |
| 2023-04-24 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2023 | |
| 2023-04-19 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-04-19 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-04-12 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-04-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | TRULANCE Drug, Gastroenterology | 2023 | |
| 2023-04-03 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-03-23 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-03-21 | GENZYME CORPORATION | $120 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-03-19 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-03-17 | Organon Llc | $28 | Food and Beverage | In-kind items and services | RENFLEXIS Drug, INFLIXIMAB | 2023 | |
| 2023-03-09 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-03-07 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-02-23 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2023 | |
| 2023-02-22 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-02-10 | QOL Medical, LLC | $10 | Food and Beverage | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2023 | |
| 2023-02-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-02-07 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-02-02 | ABBVIE INC. | $97 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-02-02 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-01-30 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-01-23 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2023 | |
| 2023-01-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-01-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | TRULANCE Drug, Gastroenterology | 2023 | |
| 2022-12-19 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2022 | |
| 2022-12-15 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 | |
| 2022-11-29 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-11-18 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-11-10 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 | |
| 2022-11-02 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 | |
| 2022-10-23 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-10-22 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-10-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-10-11 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 | |
| 2022-09-28 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-09-27 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-09-27 | Celgene Corporation | $10 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-09-20 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2022 | |
| 2022-09-19 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Mirena Drug, Womens Health | 2022 | |
| 2022-09-15 | ABBVIE INC. | $97 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-15 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2022 | |
| 2022-09-09 | QOL Medical, LLC | $14 | Food and Beverage | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | 2022 | |
| 2022-09-08 | GENZYME CORPORATION | $121 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-09-08 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2022 | |
| 2022-09-07 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10 | Food and Beverage | In-kind items and services | IBSCHEK Device, Gastroenterology | 2022 | |
| 2022-09-06 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-08-29 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | GATTEX Drug, INTERNAL MEDICINE | 2022 | |
| 2022-08-26 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2022 | |
| 2022-08-23 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-08-16 | QOL Medical, LLC | $21 | Food and Beverage | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | 2022 | |
| 2022-08-12 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-08-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-08-03 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2022 | |
| 2022-07-20 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-07-15 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2022 | |
| 2022-07-15 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-07-06 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-06-29 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-06-29 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2022 | |
| 2022-06-24 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VIBERZI Drug, GASTROENTEROLOGY | 2022 | |
| 2022-06-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-05-30 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 | |
| 2022-05-26 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-05-25 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2022 | |
| 2022-05-25 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-05-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10 | Food and Beverage | In-kind items and services | TRULANCE Drug, Gastroenterology | 2022 | |
| 2022-05-13 | Celgene Corporation | $11 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-05-13 | Celgene Corporation | $8 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-05-05 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2022 | |
| 2022-05-04 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-05-03 | Ardelyx, Inc. | $19 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2022 | |
| 2022-04-26 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-04-26 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-04-20 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2022 | |
| 2022-04-18 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | HUMIRA Biological, IMMUNOLOGY | 2022 | |
| 2022-04-16 | Ferring Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | CIMZIA Drug, GASTROENTEROLOGY | 2022 | |
| 2022-04-14 | Celgene Corporation | $10 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-04-12 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-04-11 | Medtronic, Inc. | $68 | Food and Beverage | In-kind items and services | GI GENIUS Device, Gastrointestinal AI | 2022 | |
| 2022-04-08 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | VIBERZI Drug, GASTROENTEROLOGY | 2022 | |
| 2022-03-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5 | Food and Beverage | In-kind items and services | PLENVU Drug, Gastroenterology | 2022 | |
| 2022-03-29 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-03-24 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2022 |
The latest 200 records of 644.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-06-18 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $100 | SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS | 2025 |
| 2025-06-18 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $2,500 | SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS | 2025 |
| 2025-04-09 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $1,000 | SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS | 2025 |
| 2025-01-23 | E.R. Squibb & Sons, L.L.C. | Clinical Research Professionals | $11,569 | A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | 2025 |
| 2024-12-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $2,942 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-23 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $1,500 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-12-19 | E.R. Squibb & Sons, L.L.C. | Clinical Research Professionals | $4,003 | PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) - A Phase 3, Multicenter, Open-Label Extension | 2024 |
| 2024-12-18 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-18 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-10 | Braintree Laboratories, Inc. | Clinical Research Professionals | $5,266 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-04 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $1,000 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-11-18 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $500 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-11-06 | Braintree Laboratories, Inc. | Clinical Research Professionals | $6,730 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-24 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $744 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-10-11 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $100 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-10-08 | Braintree Laboratories, Inc. | Clinical Research Professionals | $9,090 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-04 | Braintree Laboratories, Inc. | Clinical Research Professionals | $400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-03 | Braintree Laboratories, Inc. | Clinical Research Professionals | $8,755 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-03 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,519 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $15,150 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $5,200 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-09-17 | Braintree Laboratories, Inc. | Clinical Research Professionals | $5,173 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-28 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-28 | Braintree Laboratories, Inc. | Clinical Research Professionals | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-22 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-16 | Braintree Laboratories, Inc. | Clinical Research Professionals | $9,090 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-16 | Braintree Laboratories, Inc. | Clinical Research Professionals | $1,785 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-14 | Braintree Laboratories, Inc. | Clinical Research Professionals | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-14 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $744 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-08-14 | Braintree Laboratories, Inc. | Clinical Research Professionals | $6,060 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-02 | Braintree Laboratories, Inc. | Clinical Research Professionals | $6,060 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-02 | Braintree Laboratories, Inc. | Clinical Research Professionals | $2,800 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-02 | Braintree Laboratories, Inc. | Clinical Research Professionals | $400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-01 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-25 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $2,898 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $1,785 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $6,060 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $3,030 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-15 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-15 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-15 | Braintree Laboratories, Inc. | Clinical Research Professionals | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-15 | Braintree Laboratories, Inc. | Clinical Research Professionals | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-15 | Braintree Laboratories, Inc. | Clinical Research Professionals | $700 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-10 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $2,478 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-06-21 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-06-21 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-06-19 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,519 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-06-13 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $7,215 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-06-13 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $7,215 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-06-07 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $50 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $50 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $50 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $50 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-09 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-02 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $100 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-04-25 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $800 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-04-24 | E.R. Squibb & Sons, L.L.C. | Clinical Research Professionals | $4,106 | A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Bioma | 2024 |
| 2024-04-19 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $400 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-04-17 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $1,000 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-04-15 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $2,282 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-04-15 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $90 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-03-14 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $5,110 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-03-14 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $3,239 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-14 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $3,239 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-04 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $71 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-02-08 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,532 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-02-08 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,532 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-02-07 | Celgene Corporation | Clinical Research Professionals | $1,200 | PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) - A Phase 3, Multicenter, Open-Label Extension | 2024 |
| 2024-01-25 | E.R. Squibb & Sons, L.L.C. | Clinical Research Professionals | $349 | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | 2024 |
| 2024-01-24 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $2,478 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-01-15 | Braintree Laboratories, Inc. | CLINICAL RESEARCH PROFESSIONALS LLC | $2,555 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-01-10 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $279 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-01-10 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $136 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-01-10 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $584 | EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | 2024 |
| 2024-01-10 | Vanda Pharmaceuticals Inc. | CLINICAL RESEARCH PROFESSIONALS INC | $413 | SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Sullivan, MO, county Franklin County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Sullivan, MO | County Franklin County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 6,310 | 105,950 | 6,191,814 |
| Population, 2020 census P1 | 6,906 | 104,682 | 6,154,913 |
| Median age B01002 | 39.4 | 41.8 | 39.0 |
| Under 18 B01001 | 24.1% | 22.4% | 22.3% |
| 65 and over B01001 | 20.3% | 19.2% | 17.9% |
| Households B11001 | 2,722 | 43,036 | 2,508,227 |
| Foreign born B05002 | 0.1% | 1.4% | 4.5% |
| Median household income B19013 | $63,370 | $73,165 | $70,702 |
| Median family income B19113 | $85,060 | $90,136 | $91,360 |
| Per capita income B19301 | $32,875 | $37,792 | $39,695 |
| Poverty rate B17001 | 11.4% | 8.2% | 12.6% |
| Unemployment rate B23025 | 5.9% | 4.3% | 4.0% |
| Civilian labor force B23025 | 3,132 | 52,951 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.8 | 28.3 | 23.5 |
| Bachelor's degree or higher B15003 | 18.9% | 23.7% | 32.4% |
| Housing units B25001 | 2,920 | 46,312 | 2,825,287 |
| Owner-occupied B25003 | 62.4% | 76.5% | 68.1% |
| Renters B25003 | 37.6% | 23.5% | 31.9% |
| Median home value B25077 | $163,200 | $227,600 | $230,300 |
| Median gross rent B25064 | $919 | $893 | $1,033 |
| White, not Hispanic B03002 | 87.7% | 88.7% | 76.3% |
| Black B03002 | 1.5% | 0.9% | 10.9% |
| Hispanic or Latino B03002 | 0.8% | 2.3% | 5.2% |
| Asian B03002 | 0.0% | 0.4% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Sullivan, MO.
Comments